We and others have previously shown that NSCLC cells carrying an oncogenic KRAS mutation exhibit primary resistance to anti-EGFR therapy with small molecule inhibitors such as erlotinib, and propose that these KRAS-addicted cells subvert upstream signals emanating from EGFR [28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.